RU2012102424A - SELECTIVE INHIBITORS Haspin KINASES - Google Patents
SELECTIVE INHIBITORS Haspin KINASES Download PDFInfo
- Publication number
- RU2012102424A RU2012102424A RU2012102424/04A RU2012102424A RU2012102424A RU 2012102424 A RU2012102424 A RU 2012102424A RU 2012102424/04 A RU2012102424/04 A RU 2012102424/04A RU 2012102424 A RU2012102424 A RU 2012102424A RU 2012102424 A RU2012102424 A RU 2012102424A
- Authority
- RU
- Russia
- Prior art keywords
- pyridin
- dihydrochloride
- imidazo
- chlorimidazo
- alkyl
- Prior art date
Links
Abstract
1. Соединение общей формулы (I)(I) или любая его таутомерная форма, или его фармацевтически приемлемая соль, где каждый из Х, Х, Х, Х, Х, Хвыбран из N или С;Хвыбран из N или СН;каждый из Х, Х, Xи Хнезависимо выбран из N или СН при условии, что фрагмент может одновременно содержать один или два атома азота;R, R, Rи Rвыбраны из Н, Салкила, 6-14-членного арила, ОСалкила, CF, галогена, СООН, СООСалкил, CONH, CON(Cалкил), CN, N(Cалкил), 4-14-членного гетероарила, содержащего, по крайней мере один гетероатом, выбранный из азота и кислорода;R, R, Rвыбраны из Салкила, галогена, CN при условии, что Х, Хили Хв этом случае соответственно равен С;"А" может представлять собой простую связь или мостиковый этиновый фрагмент;Y может представлять собой простую связь, или независимо выбран из метиленового или этиленового мостиковых фрагментов;фрагмент Z независимо выбран из незамещенного или замещенного по атому азота гетероциклоалкила, или является незамещенным или замещенным циклоалкилом при условии, что N (азот) равно С (углерод):где Rвыбран из ОН, F, ОСалкила, NH, NH(Салкил), N(Cалкил), СНОН, CON(RR), где R, Rмогут независимо представлять собой Н, Салкил, Сциклоалкил, 6-14-членный арил, 4-14-членный гетероарил, содержащий, по крайней мере один гетероатом, выбранный из азота и кислорода, илиRможет представлять собой следующие гетероциклические заместители:где Y, Y=Н или С-Салкил.Rвыбран из Н, Салкала,циклоалкила и гетероциклоалкила общего строения:,Салкилкарбонила, Сциклоалкалкарбонила,гетероциклоалкилкарбонила общего строения:,арилкарбонилов общего строения:гетероарилкарбонилов общего строения:производных алкил-, циклоалкил-, гетероциклоалкил-, арил-, или гетероарилуксусной кислот1. The compound of general formula (I) (I) or any tautomeric form thereof, or a pharmaceutically acceptable salt thereof, wherein each of X, X, X, X, X, is selected from N or C; selected from N or CH; each X, X, X, and X are independently selected from N or CH, provided that the fragment can simultaneously contain one or two nitrogen atoms; R, R, R and R are selected from H, C1-6alkyl, 6-14 membered aryl, OSalkyl, CF, halogen, COOH , COOSalkyl, CONH, CON (C1-6alkyl), CN, N (C1-6alkyl), a 4-14 membered heteroaryl containing at least one heteroatom selected from nitrogen and oxygen; R, R, R are selected from C1-6alkyl, halogen, CN at condition that X, Healy X in this case is respectively C; “A” may be a single bond or a bridged ethylene moiety; Y may be a single bond or is independently selected from methylene or ethylene bridged fragments; the Z moiety is independently selected from unsubstituted or heterocycloalkyl substituted at the nitrogen atom, or is unsubstituted or substituted cycloalkyl provided that N (nitrogen) is equal to C (carbon): where R is selected from OH, F, OSalkyl, NH, NH (C1-6alkyl), N (C1-6alkyl), CHOH, CON (RR), where R, R may independently be H, C1-6alkyl, Cycloalkyl, 6-14 membered aryl, 4-14 membered heteroaryl containing at least one heteroatom selected from nitrogen and oxygen, or R may be the following heterocyclic substituents: where Y, Y = H or C- C1-6alkyl, selected from H, Salkal, cycloalkyl and heterocycloalkyl of the general structure:, C1-6alkylcarbonyl, Cycloalkylcarbonyl, heterocycloalkylcarbonyl of the general structure:
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2012102424/04A RU2548363C2 (en) | 2012-01-25 | 2012-01-25 | SELECTIVE INHIBITORS OF Haspin kinase |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2012102424/04A RU2548363C2 (en) | 2012-01-25 | 2012-01-25 | SELECTIVE INHIBITORS OF Haspin kinase |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2012102424A true RU2012102424A (en) | 2013-07-27 |
RU2548363C2 RU2548363C2 (en) | 2015-04-20 |
Family
ID=49155451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012102424/04A RU2548363C2 (en) | 2012-01-25 | 2012-01-25 | SELECTIVE INHIBITORS OF Haspin kinase |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2548363C2 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
US11427567B2 (en) | 2019-08-14 | 2022-08-30 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
US11851426B2 (en) | 2019-10-11 | 2023-12-26 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
US11976073B2 (en) | 2022-12-09 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4049726A1 (en) * | 2021-02-25 | 2022-08-31 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Imidazo[1,2-a]pyrazines as inhibitors of haspin and therapeutic uses thereof |
-
2012
- 2012-01-25 RU RU2012102424/04A patent/RU2548363C2/en not_active IP Right Cessation
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US11866432B2 (en) | 2018-10-11 | 2024-01-09 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
US11427567B2 (en) | 2019-08-14 | 2022-08-30 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors |
US11851426B2 (en) | 2019-10-11 | 2023-12-26 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
US11976073B2 (en) | 2022-12-09 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Also Published As
Publication number | Publication date |
---|---|
RU2548363C2 (en) | 2015-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2012102424A (en) | SELECTIVE INHIBITORS Haspin KINASES | |
JP7418395B2 (en) | SHP2 phosphatase inhibitors and methods of using them | |
AU2015296322B2 (en) | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof | |
AU2017346516B2 (en) | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | |
AU2020282473A1 (en) | Nitrogen-containing heterocyclic derivative regulator, preparation method therefor and application thereof | |
AU2015271837B2 (en) | Tank-binding kinase inhibitor compounds | |
AU2014375500B2 (en) | Kinase inhibitor and use thereof | |
EP3728264B1 (en) | Diazaindole compounds | |
KR20150086248A (en) | Azaquinazoline inhibitors of atypical protein kinase c | |
AU2013225533A1 (en) | Amido spirocyclic amide and sulfonamide derivatives | |
US20190231775A1 (en) | Methods of Blocking the CXCR-4/SDF-1 Signaling Pathway With Inhibitors of Bruton's Tyrosine Kinase | |
AU2010310786A1 (en) | AKT inhibitors | |
BR112020012651A2 (en) | compounds derived from aryl-bipyridine amine as inhibitors of phosphatidylinositol phosphate kinase, pharmaceutical composition comprising the same and therapeutic uses of said compounds | |
CN117651700A (en) | 2-aminobenzothiazole compounds and methods of use | |
AU2023201522A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
TW202321242A (en) | Heterocyclic compounds and methods of use | |
EP4237086A1 (en) | Heterocyclic spiro compounds and methods of use | |
EP4313983A1 (en) | (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo [1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer | |
US20230083376A1 (en) | BRM Targeting Compounds And Associated Methods Of Use | |
RU2011126981A (en) | Derivatives of 6-cycloamino-3- (1H-pyrrolo [2,3-b] pyridin-4-yl) imidazo [1,2-b] pyridazine, their production and use in therapy | |
WO2015185998A2 (en) | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase | |
CN117897159A (en) | Heterocyclic compounds and methods of use | |
RU2011132796A (en) | NEW DERIVATIVES OF NITROGEN-CONTAINING SATURATED CARBOCYCLES AS INHIBITORS OF MUSCARINE RECEPTORS, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS AND METHOD FOR INHIBITING ACTIVITIES OF MUTUAL ACTIVITY. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HE9A | Changing address for correspondence with an applicant | ||
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20140122 |
|
FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20140424 |
|
PC41 | Official registration of the transfer of exclusive right |
Effective date: 20160615 |
|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20170126 |